Exsure, a biotech startup based in Bhubaneswar, has secured Rs 3 crore in a seed funding round led by Unicorn India Ventures. The company plans to utilize the funds to achieve key milestones in its non-clinical studies and expand its presence globally. Additionally, Exsure will focus on promoting its in-house R&D products, including Exosure, Leucosure, PlantExosure, and Dr Berries.
What Does Exsure Do?
Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure aims to revolutionize cancer treatment with its patented exosomal drug-delivery platform. This innovative technology targets cancer and cancer stem cells, reducing the side effects and toxicity of chemotherapy. By minimizing the harmful effects of cancer drugs. After new seed funding, Exsure strives to improve the quality of life for cancer patients and lower the risk of relapse.
Swastika Paul, Co-founder and CSO of Exsure, shared her vision, stating, “During our PhD journey, we saw the devastating effects of chemotherapy toxicity. Around 13% of cancer patients undergoing treatment die due to drug toxicity. Exsure is committed to reducing these side effects and making cancer treatments more targeted and effective. Our goal is to empower millions of cancer patients worldwide.”
Exsure Market Presence
Over the past year, Exsure has made significant strides in its mission. The company has initiated non-clinical studies in India in partnership with a Contract Research Organization (CRO). Using its patented technology, it has successfully completed a key milestone in its preclinical study.
Exsure has also reported remarkable growth, achieving a fivefold increase in revenue last fiscal year. The startup is on track to serve over 50 clients with its innovative R&D products, including:
- Exosure: A 3-in-1 exosome isolation reagent.
- Leucosure: A PBMC isolation reagent.
- PlantExosure: India’s first plant exosome isolation reagent.
The company has been selected for the prestigious OIST Innovation Accelerator program in Japan. This opportunity will support Exsure in expanding its business and conducting clinical trials.
Plans After Seed Funding
In the coming year, Exsure aims to complete its non-clinical study and present its data to the Central Drugs Standard Control Organization (CDSCO) for approval. The startup also plans to strengthen its team, enhance product marketing and sales, and expand its global footprint.
India’s biotechnology industry is rapidly growing, with expectations to reach $150 billion by 2025 and $270-300 billion by 2030, according to IBEF. By 2025, the industry’s contribution to the global market is projected to grow to 19%.
Bhaskar Majumdar, Managing Partner at Unicorn India Ventures, praised Exsure’s innovation, stating, “Exsure is addressing the real fear of cancer with advanced scientific tools and cutting-edge medical research. This funding will help the company deploy its solutions on a global scale.”
